EML4 and non-small cell lung carcinoma: In agreement with our observations for NPM-ALK (Table 1; Figure 2C; Supplementary Figure S2), F1174L results in resistance to crizotinib in both ALK+ NSCLC and ALK+ IMT [55–57], although we did not observe a significant change in resistance in our EML4-ALK in vitro assay (p = 0.4846; Table 4; Figure 2E; Supplementary Figure S4).